Figure 4.

Response of T-ALL primary samples (n = 2) and patient derived xenografts (n = 5) to small molecule inhibitors (n = 31). (A) The heatmap represents the mean EC₅₀ values obtained for the samples treated with the drugs for 48 hr under normoxic conditions. The columns indicate T-ALL samples and the rows indicate the tested drugs. The darkest red indicates the most sensitivity (lowest EC₅₀ values) of the tested samples to the tested inhibitors. EC₅₀ values are only reported for compounds that yielded a maximum response values of 20% or greater. For those samples which yielded maximal responses < 20% and/or had EC₅₀ values greater than 100 µM, we report those EC₅₀ values as “100 µM” (light grey). (B) The maximum responses of each T-ALL sample to the tested inhibitors at the highest tested dose, 100 µM, with exception of *alvocidib, *bortezomib and *carfilzomib, for which the highest tested dose was 1 µM. The heatmap indicates the levels of percentage of dead cells, where darkest red indicates 100% propidium iodide positive cells. (C) Representative high throughput dose response curves of T-ALL samples (primary samples, 12–089 and 15–093; patient derived xenografts, PATRAP, PATZZM) treated with the tested inhibitors. The cells were treated in dose responses (afatinib and sunitinib, 0.005 – 100 µM; carfilzomib, 0.05 – 1000 nM) for 48 hr, followed by cell viability analyses by flow cytometry using propidium iodide.